Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul 19;58(4):395-401.
doi: 10.1016/j.jacc.2011.03.031.

A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study

Affiliations

A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study

Margaret C Fang et al. J Am Coll Cardiol. .

Abstract

Objectives: The purpose of this study was to develop a risk stratification score to predict warfarin-associated hemorrhage.

Background: Optimal decision making regarding warfarin use for atrial fibrillation requires estimation of hemorrhage risk.

Methods: We followed up 9,186 patients with atrial fibrillation contributing 32,888 person-years of follow-up on warfarin, obtaining data from clinical databases and validating hemorrhage events using medical record review. We used Cox regression models to develop a hemorrhage risk stratification score, selecting candidate variables using bootstrapping approaches. The final model was internally validated by split-sample testing and compared with 6 published hemorrhage risk schemes.

Results: We observed 461 first major hemorrhages during follow-up (1.4% annually). Five independent variables were included in the final model and weighted by regression coefficients: anemia (3 points), severe renal disease (e.g., glomerular filtration rate <30 ml/min or dialysis-dependent, 3 points), age ≥75 years (2 points), prior bleeding (1 point), and hypertension (1 point). Major hemorrhage rates ranged from 0.4% (0 points) to 17.3% per year (10 points). Collapsed into a 3-category risk score, major hemorrhage rates were 0.8% for low risk (0 to 3 points), 2.6% for intermediate risk (4 points), and 5.8% for high risk (5 to 10 points). The c-index for the continuous risk score was 0.74 and 0.69 for the 3-category score, higher than in the other risk schemes. There was net reclassification improvement versus all 6 comparators (from 27% to 56%).

Conclusions: A simple 5-variable risk score was effective in quantifying the risk of warfarin-associated hemorrhage in a large community-based cohort of patients with atrial fibrillation.

PubMed Disclaimer

Conflict of interest statement

Potential Financial Conflicts of Interest: D.E. Singer has consulted for Boehringer Ingelheim, Daiichi Sankyo, Inc., Johnson & Johnson, Inc., Merck and Co., Bayer Schering Pharma, and Sanofi Aventis, Inc., and has received research support from Daiichi Sankyo, Inc. A.S. Go has received research support from Johnson & Johnson, Inc.

Figures

Figure
Figure. Distribution of Cohort Person-years and Hemorrhage Events by Risk Categories
Blue bars show the proportion of cohort person-years in low, intermediate, and high bleeding risk categories. Purple bars show the proportion of the total hemorrhage events (n=461) captured by each risk category.

Comment in

Similar articles

Cited by

References

    1. Hart R, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine. 2007;146:857–867. - PubMed
    1. Bungard TJ, Ghali WA, McAlister FA, et al. The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Canadian Journal of Cardiology. 2003;19:280–284. - PubMed
    1. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Annals of Internal Medicine. 1999;131:927–934. - PubMed
    1. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685–2692. - PubMed
    1. Beyth R, Quinn L, Landefeld C. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91–99. - PubMed

Publication types